U.S. Markets
Merck's (MRK) Ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer has been accepted for FDA priority review
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
